Ifosfamide in advanced/disseminated breast cancer.
Oncology
; 65 Suppl 2: 55-8, 2003.
Article
em En
| MEDLINE
| ID: mdl-14586149
ABSTRACT
Ifosfamide is an alkylating agent active in various tumor types including breast cancer. The availability of mesna (sodium 2-mercaptoethanesulfonate) has increased its safety, avoiding the main dose-limiting side effect, urotoxicity. Interesting activity as a single agent, with response rates ranging from 7 to 30%, is reported in pretreated patients; more attractive data derived from phase II studies on ifosfamide combined with drugs known to be active in advanced breast cancer show response rates always over 35%. This review has taken in consideration papers published after 1995 and available on PubMed medline the data indicate a potential usefulness of ifosfamide in the clinical management of advanced breast cancer, even if the exact therapeutic role of the drug in this setting should be derived from randomized studies not yet available.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Vimblastina
/
Neoplasias da Mama
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Antineoplásicos Alquilantes
/
Ifosfamida
Tipo de estudo:
Clinical_trials
/
Systematic_reviews
Limite:
Female
/
Humans
Idioma:
En
Ano de publicação:
2003
Tipo de documento:
Article